← Back to Search

ASL Services for Hearing Loss (FASL Trial)

N/A
Recruiting
Led By Diane C Lillo-Martin, Ph.D.
Research Sponsored by University of Connecticut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participating in a program utilizing a bimodal bilingual philosophy
Child is Deaf/ Hard-of-Hearing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 months
Awards & highlights

FASL Trial Summary

This trial looks at how DHH children and their parents develop American Sign Language skills.

Who is the study for?
This study is for deaf or hard of hearing children aged between 2 to almost 3 years, who are part of a program that supports both spoken and sign language learning. They must have an adult caregiver involved. Children with other conditions affecting language/cognitive skills or families without internet access cannot participate.Check my eligibility
What is being tested?
The trial is exploring how services supporting the learning of American Sign Language (ASL) affect the development of ASL in deaf and hard of hearing children as well as their parents over time.See study design
What are the potential side effects?
Since this trial involves educational services rather than medical interventions, there are no direct physical side effects associated with participating in this study.

FASL Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am part of a program that uses both sign language and spoken language.
Select...
My child is deaf or hard-of-hearing.
Select...
My child is between 2 years and 2 years 11 months old.

FASL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in ASL Phonological Production Accuracy over 12 Months
Secondary outcome measures
Change from Baseline in ASL Production Frequency over 12 Months

FASL Trial Design

2Treatment groups
Experimental Treatment
Group I: ASL Services - Child Language DevelopmentExperimental Treatment1 Intervention
Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
Group II: ASL Services - Adult ASL DevelopmentExperimental Treatment1 Intervention
Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency

Find a Location

Who is running the clinical trial?

University of ConnecticutLead Sponsor
181 Previous Clinical Trials
158,156 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
327 Previous Clinical Trials
178,276 Total Patients Enrolled
54 Trials studying Hearing Loss
19,910 Patients Enrolled for Hearing Loss
Diane C Lillo-Martin, Ph.D.Principal InvestigatorUniversity of Connecticut

Media Library

ASL Services Clinical Trial Eligibility Overview. Trial Name: NCT04988451 — N/A
Hearing Loss Research Study Groups: ASL Services - Adult ASL Development, ASL Services - Child Language Development
Hearing Loss Clinical Trial 2023: ASL Services Highlights & Side Effects. Trial Name: NCT04988451 — N/A
ASL Services 2023 Treatment Timeline for Medical Study. Trial Name: NCT04988451 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research program currently open to participants?

"According to clinicaltrials.gov, this study is actively seeking out new participants after it's initial listing on July 20th 2021; and with the latest update being published on July 26th of that same year."

Answered by AI

How many individuals is the trial recruiting?

"Affirmative, the information hosted on clinicaltrials.gov denotes that this experimental treatment is currently recruiting volunteers. The trial was first announced on July 20th 2021 and later modified on July 26th 2021, with an aim to enroll 40 patients at a single medical facility."

Answered by AI
~0 spots leftby Mar 2024